Phaseline

Targets › GAN

GAN (Gigaxonin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2031.

Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. (UniProt, Q9H2C0)

Open in Phaseline: the race on GAN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Texas Southwestern Medical CenterscAAV9/JeT-GAN
Self-complementary adeno-associated virus serotype 9 (scAAV9) delivering GAN gene for gene
GANPhase 1Giant Axonal Neuropathy (GAN)Dec 2031

Conditions

Giant Axonal Neuropathy (GAN) (1)

Modalities

other (1)

Companies

University of Texas Southwestern Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.